Erythrocytes as Drug Carriers in Medicine

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology
Cover of the book Erythrocytes as Drug Carriers in Medicine by , Springer US
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781489900449
Publisher: Springer US Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9781489900449
Publisher: Springer US
Publication: June 29, 2013
Imprint: Springer
Language: English

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop­ ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In­ deed, clinical trials were initiated to evaluate the dose-response curves employing L­ asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap­ proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac­ tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop­ ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In­ deed, clinical trials were initiated to evaluate the dose-response curves employing L­ asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap­ proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac­ tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy.

More books from Springer US

Cover of the book Clinical Applications of Medical Imaging by
Cover of the book Principles and Applications of Modified Atmosphere Packaging of Foods by
Cover of the book Can a Virus Cause Schizophrenia? by
Cover of the book Invertebrate Models for Biomedical Research by
Cover of the book Contemporary Internal Medicine by
Cover of the book Insects, Experts, and the Insecticide Crisis by
Cover of the book Electron Energy-Loss Spectroscopy in the Electron Microscope by
Cover of the book Planetary Landscapes by
Cover of the book Drug and Alcohol Abuse by
Cover of the book Pediatric Brain Death and Organ/Tissue Retrieval by
Cover of the book An Agenda for Action by
Cover of the book Computer-Based Diagnostics and Systematic Analysis of Knowledge by
Cover of the book Supported Complex and High Risk Coronary Angioplasty by
Cover of the book Elderly People and the Environment by
Cover of the book The Preparation of Monetary Policy by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy